DIRS.INFO The most relevant business & tech news

☆ Postpandemic Hangover Spreads to New Group of Healthcare Companies
▼ + stars: | 2023-05-10 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Companies like Thermo Fisher reported outsize growth during the Covid-19 pandemic. Photo: yves herman/ReutersFor drug companies, Covid-19 brought financial gains that were unevenly distributed, with Pfizer making over $50 billion from pandemic-related products last year even as other pharma companies saw more modest sales boosts. By contrast, the pandemic wealth was more evenly spread for “picks-and-shovels” businesses that supply big pharma companies with products needed to manufacture drugs and vaccines.

☆ Investment consortium to take Syneos private for $4.46 billion
▼ + stars: | 2023-05-10 | by ( ) www.reuters.com time to read: +2 min

May 10 (Reuters) - An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to take Syneos Health Inc (SYNH.O) private for $4.46 billion, the contract research firm said on Wednesday. Syneos said the consortium will pay about $43 per share in cash, which represents a premium of about 12% to the company's last close of $38.45. The acquisition is valued at $7.1 billion including debt. Syneos, which helps pharmaceutical companies with clinical trials and marketing their drugs, currently carries a debt of nearly $3 billion. The company reported a total backlog of contracts of $9.83 billion, as of March 31, 2023, down from $11.63 billion at the end of the first quarter of 2022.

☆ Pharma Suppliers Are Nursing a Postpandemic Hangover
▼ + stars: | 2023-05-09 | by ( David Wainer | ) www.wsj.com time to read: 1 min

The buyout consortium has turned to other private equity firms to help fund the deal as direct lenders, one of the sources added. There is no certainty that Warburg Pincus and Advent will successfully complete negotiations to acquire the unit and Baxter may still opt to sell to another bidder or keep the business, according to the sources. Baxter, Warburg and Advent did not immediately respond to requests for comment. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines. The company said dialysis operations, which are a part of Baxter's renal care unit, had become a drag on its margin.

☆ BANK OF AMERICA: Buy these 16 healthcare stocks to capture their collective 50% upside ahead of a sector rally
▼ + stars: | 2023-05-07 | by ( Marley Jay | ) www.businessinsider.com time to read: +3 min

Bank of America says healthcare stocks are usually strong performers in economic downturns. Their solid earnings and low valuations should help healthcare stocks going forward. The firm named 16 favorite stocks in the sector, including 3 that it thinks could double in price. Healthcare stocks aren't having a great year, but Bank of America says it sees signs that the tide is going to turn. Bank of America says the following 16 names are the best defensive and high-upside small- and mid-cap stocks in healthcare.

☆ Croatia clears mystery clumps of oil from beaches before tourists arrive
▼ + stars: | 2023-04-27 | by ( Antonio Bronic | ) www.reuters.com time to read: +2 min

No official explanation has been given for the pollution, which has stuck, in small patches, to the rocks and wild limestone beaches near the town of Pula. This is not the first time oil had drifted ashore in the area, she said, and people deserve to know the cause. "We cannot just wait and fear each year that wind will bring us a new oil spill," Buttignoni told Reuters. "There will be a problem because this (oil) constantly keeps coming though in smaller quantities," said villager Giuliano. "There will be a problem with tourism, when guests arrive and probably step on it.

☆ Morning Bid: Cloud control - tech trumps banks
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +5 min

Alphabet (GOOGL.O) also gained 1% as it too trumpeted gains in cloud services and AI, alongside plans for a $70 billion buyback. With Meta (META.O) results out later, its stock was up 2% and Amazon (AMZN.O) raced ahead 4%. PacWest Bancorp's (PACW.O) shares jumped 15% in extended trading after the regional lender said deposits have been building recently. And in Europe, Standard Chartered (STAN.L) shares bucked otherwise dour markets on a forecast-beating 21% jump in first-quarter profits. U.S. Treasury markets continued to rally, with yields on 2-year notes dropping below 4% Tuesday and testing 3.9% early today.

☆ Stocks making the biggest moves premarket: Activision Blizzard, Chipotle, First Republic Bank & more
▼ + stars: | 2023-04-26 | by ( Pia Singh | ) www.cnbc.com time to read: +5 min

The company said Tuesday its upcoming quarterly revenue will range from $700 million to $750 million, compared to the expected $765.2 million from analysts surveyed by StreetAccount. The company reported an adjusted loss of $1.27 per share and $17.92 billion in revenue. Activision Blizzard — Activision Blizzard shares dropped about 10.4% in the premarket after a UK regulator blocked Microsoft's purchase of the video game publisher. ServiceNow will be announcing its quarterly earnings Wednesday after the bell. The gain came after fellow tech-related giant Microsoft reported quarterly earnings that exceeded expectations, boosting sentiment for Amazon.

☆ Big Tech earnings, crucial inflation call — here comes the biggest week of earnings season
▼ + stars: | 2023-04-22 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks stuck to a holding pattern this week as investors brace for an incoming wave of Big Tech earnings and the Fed's favorite inflation reading. Earnings reports have generally been better than expected so far this first quarter. Humana (HUM) reports before the bell Wednesday; Meta Platforms and Pioneer Natural Resources (PXD) report after the bell Wednesday. ET: Personal Spending & Income (includes PCE Price Index) Club trades this week Just one trade: We added 150 shares of Coterra Energy (CTRA) on Wednesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Final Trades: Biotech, Defense, Thermo Fisher & more
▼ + stars: | 2023-04-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Biotech, Defense, Thermo Fisher & moreThe "Halftime Report" traders give their top picks to watch for the second half.

☆ Buy these stocks with fortress balance sheets to win in the slowing economy, Morgan Stanley says
▼ + stars: | 2023-04-10 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Companies with strong balance sheets have a downside cushion and can find unique opportunities during a slowing economy, according to Morgan Stanley. Corporations with high amounts of cash on their balance sheets can take advantage of a slowing economy by buying back their stock or acquiring businesses at discounted prices, said Morgan Stanley strategist Todd Castagno. "We've identified companies with strong balance sheets and sufficient liquidity, that also generate excess returns over their cost of capital," Castagno said in a note to clients. Investors have been increasingly focused on the strength of corporate balance sheets amid rising concerns that the Federal Reserve's series of interest rate hikes could tip the U.S. economy into a slowdown or recession. Castagno screened the Russell 1000 , except for financials, real estate and utilities, to find companies with fortress-like balance sheets.

☆ Final Trades: Abbvie, Thermo Fisher & more
▼ + stars: | 2023-04-05 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Abbvie, Thermo Fisher & moreThe "Halftime Report" traders give their top picks to watch for the second half.

☆ Jim Cramer's top 10 things to watch in the stock market Tuesday: ServiceNow bump, Dimon speaks, DHR cut
▼ + stars: | 2023-04-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +3 min

Baird upgrades software stock ServiceNow (NOW) to buy from hold, with a price target of $548, up from $475. Raises price target to $140 from $135. Barclays turns on life science tools and diagnostics sector, drops price target for Club favorite Danaher (DHR) to $270 from $290 and expects a "relatively light" first-quarter guide. Norfolk Southern (NSC) upgraded to hold from sell at Morgan Stanley with unchanged price target of $171. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Blue Origin says an overheated engine part caused last year's cargo rocket failure
▼ + stars: | 2023-03-24 | by ( Michael Sheetz | ) www.cnbc.com time to read: +2 min

The moment of the anomaly during the New Shepard cargo mission NS-23, in which the booster's engine failed. The company's New Shepard rocket, flying the NS-23 mission carrying science and research payloads, suffered a failure in September 2022. No people were onboard, and Blue Origin says its capsule's emergency escape system functioned properly, but the rocket's reusable booster was destroyed. "Blue Origin expects to return to flight soon, with a re-flight of the NS-23 payloads," the company said. The New Shepard rocket booster is reusable, returning to land on a concrete pad near the launch site.

March 20 (Reuters) - U.S. scientific instruments maker Thermo Fisher Scientific Inc (TMO.N) and South Korea's Celltrion Inc (068270.KS) are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (BAX.N), according to people familiar with the matter. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co (KKR.N) and Carlyle Group (CG.O), have also expressed interest in the Baxter business, the sources said. Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.

☆ Here are Thursday's biggest analyst calls: Credit Suisse, Amazon, Block, First Republic, FedEx & more
▼ + stars: | 2023-03-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: JPMorgan reiterates Amazon as overweight JPMorgan said growth deceleration concerns are overdone. Stifel upgrades FedEx to buy from hold Stifel said FedEx shares are compelling at current levels. JPMorgan reiterates Credit Suisse as overweight JPMorgan said it's standing by shares of the banking giant. JPMorgan upgrades Motorola Solutions to overweight from neutral JPMorgan called the telecom equipment company "high quality." Bank of America upgrades Takeda Pharmaceuticals to buy from neutral Bank of America said called Takeda a "stable value stock."

Reuters reported in March 2020 that Syneos was working with investment bank Centerview Partners LLC to explore a sale. Syneos, which has a market capitalization of $3.9 billion and carries a $2.9 billion debt pile, was not immediately available for comment. Based in Morrisville, North Carolina, Syneos helps pharmaceutical companies with clinical trials and to market their drugs. There has been a wave of consolidation among contract research organizations in a bid to lower costs, amass more clinical trial data and win customers. Labcorp (LH.N), for example, said earlier this month that it will complete the spinoff of its contract research organization, called Fortrea, by the middle of this year.

☆ Cramer's lightning round: Parker-Hannifin is a buy
▼ + stars: | 2023-02-07 | by ( Krystal Hur | ) www.cnbc.com time to read: +1 min

I would buy it here." Waste Management Inc : "Everyone thought that quarter was not that great and was telling me to buy Republic Services . Loading chart...Illumina Inc : "If you're going to be in that business, there's only two. Loading chart...TG Therapeutics Inc : "This is [run by CEO] Mike Weiss. I think that you've got a winner, and I need to hear it from you."

☆ Coterra, Danaher and TJX Companies are in the news. Here's our take on the headlines
▼ + stars: | 2023-02-06 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

A trio of Club stocks — Coterra Energy (CTRA), Danaher (DHR) and TJX Companies (TJX) — are in the news Monday. The multiweek slide in natural gas prices is at the heart of Raymond James' downgrade because Coterra's revenue is split roughly 50-50 between natural gas and oil. @NG.1 5Y mountain Natural Gas prices over 5 years The Club's take: The decline in natural gas prices is undoubtedly going to affect the amount of cash Coterra generates and then returns to shareholders via its fixed-plus-variable dividend strategy and buybacks. We're not heading for the exits on Coterra despite the decline in natural gas prices. A photo of a natural gas flare burning near an oil pump jack at the New Harmony Oil Field in the U.S. on June 19, 2022.

☆ Illumina Makes Its Interim CFO Permanent
▼ + stars: | 2023-02-01 | by ( Kristin Broughton | ) www.wsj.com time to read: +3 min

Gene-sequencing company Illumina Inc. on Wednesday named Joydeep Goswami as chief financial officer, giving its interim CFO the role on a permanent basis. Mr. Goswami joined Illumina in 2019 as chief strategy and corporate development officer, overseeing strategic partnerships and acquisitions. Illumina CFO Joydeep Goswami. He added that he received a crash course in traditional areas of finance, including treasury, tax and audit, while serving as interim CFO. As CFO, Mr. Goswami plans to keep Illumina’s spending on innovation roughly constant as a percentage of revenue.

☆ Morning Bid: A quart and two halves
▼ + stars: | 2023-02-01 | by ( ) www.reuters.com time to read: +5 min

A look at the day ahead in U.S. and global markets from Mike Dolan. February kicked off on Wednesday without too much trepidation about how all that will pan out. Before the Fed announcement, ADP releases its January private sector employment readout for last month and markets will also scan the December JOLTS job openings report. While markets await the 'Triple-A' of Big Tech releases on Thursday, Meta (META.O) is due to report later today and the dour news from elsewhere in the tech sector kept coming. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ Final Trades: Darden Restaurants, Thermo Fisher & more
▼ + stars: | 2023-02-01 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Darden Restaurants, Thermo Fisher & moreThe "Halftime Report" traders give their top picks to watch for the second half.

☆ Here comes the biggest week of earnings. Plus an AI ode to the Dow
▼ + stars: | 2023-01-28 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

While only six companies in the Dow Jones Industrial Average are reporting next week, about 20% of the S & P 500 reports, making it the biggest week of earnings this season. The Dow and the S & P 500 gained 2.2% and 2.9% this week, respectively, while the Nasdaq Composite rose 4.7%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ Stocks may face an inflection point in the week ahead as the Fed meets and Apple posts earnings
▼ + stars: | 2023-01-27 | by ( Patti Domm | In | ) www.cnbc.com time to read: +9 min

The Fed's meeting Tuesday and Wednesday comes amid a flood of corporate earnings reports, with about 20% of the S & P 500 reporting that week. The most important day for earnings is Thursday, when Apple , Alphabet and Amazon report after the bell. The Nasdaq Composite was up 11% for the month as of Friday afternoon, well ahead of the 6.2% gain in the S & P 500. Traders have been watching the S & P 500 edge closer to the key threshold of 4,100 , its high from December. AAPL 1Y line apple Apple is also important because of the signals it can send about the strength of the consumer, supply chains and China's reopening.

Search resuls for: "Thermo"

25 mentions found